Advances In Antibody Therapeutics Depend On Resin Innovation

As antibody therapeutics transforms health care and treatments for diseases such as cancer and autoimmune disorders, the biotech and pharmaceutical companies are making significant investments to meet a growing demand. The global market for monoclonal antibodies is currently forecasted to reach $647 billion by 2032.

Chromatographic resins are important in the development of antibody therapeutics because they separate and purify monoclonal antibodies from the proteins, DNA, and impurities that are part of the development process. Thanks to new products such as Praesto Jetted A50 HipH from Purolite, steps are being taken forward with Protein A resin technology that will help address resin availability and other concerns.